Literature DB >> 16799982

Magnetic resonance imaging correlated with the histopathological effect of Pd-bacteriopheophorbide (Tookad) photodynamic therapy on the normal canine prostate gland.

Zheng Huang1, Masoom A Haider, Susan Kraft, Qun Chen, Dominique Blanc, Brian C Wilson, Fred W Hetzel.   

Abstract

BACKGROUND AND
OBJECTIVE: To determine the optimal magnetic resonance imaging (MRI) methodology to assess photodynamic therapy (PDT)-induced histopathological responses in the prostate. STUDY DESIGN/
MATERIALS AND METHODS: Laparotomy was performed in five healthy dogs. Cylindrical diffuser was placed in the prostates to deliver light of 50-300 J/cm at 150 mW/cm and 763 nm to activate IV-injected Tookad (1 mg/kg b.w.). Fast spin echo (FSE) T2-weighted, post-contrast-enhanced T1-(CE-T1) and diffusion weighted images (DWI) were obtained pre- and 2 days, 7 days, and 1 month post-PDT. Radiological-histopathological correlation was performed at 7 days (n = 4) and 1 month (n = 1) after PDT. A qualitative assessment of signal changes and apparent diffusion coefficient (ADC) mapping was performed.
RESULTS: At 2 or 7 days post-PDT, there was good spatial correlation between PDT-induced hemorrhagic necrosis and unenhanced regions on CE-T1 images. There was a rapidly and persistently enhancing rim corresponding to edema and inflammation. FSE T2 and DWI showed altered signal but did not clearly define necrosis in all cases. At 1 month, it was hard to correlate MR images to histopathologic changes as they represented a mixture of necrosis and developing fibrosis, which led to a mixed signal intensity and less demarcated contrast enhancement.
CONCLUSIONS: At 7 days after PDT, gadolinium DTPA contrast-enhanced MRI is superior to DWI and T2 imaging in assessing the boundary of Tookad PDT-induced tissue necrosis in the normal canine prostate. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799982      PMCID: PMC1850616          DOI: 10.1002/lsm.20375

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  32 in total

1.  Multishot diffusion-weighted FSE using PROPELLER MRI.

Authors:  James G Pipe; Victoria G Farthing; Kirsten P Forbes
Journal:  Magn Reson Med       Date:  2002-01       Impact factor: 4.668

2.  PDT with TOOKAD(®) studied in the chorioallantoic membrane of fertilized eggs.

Authors:  Angelika Rück; Andrea Böhmler; Rudolf Steiner
Journal:  Photodiagnosis Photodyn Ther       Date:  2005-03       Impact factor: 3.631

3.  Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI.

Authors:  Dominique Jennings; B Nicholas Hatton; Jingyu Guo; Jean-Philippe Galons; Theodore P Trouard; Natarajan Raghunand; James Marshall; Robert J Gillies
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

4.  Quantitative microbubble enhanced transrectal ultrasound as a tool for monitoring hormonal treatment of prostate carcinoma.

Authors:  Robert J Eckersley; J P Michiel Sedelaar; Martin J K Blomley; Hessel Wijkstra; Nandita M deSouza; David O Cosgrove; Jean J M C H de la Rosette
Journal:  Prostate       Date:  2002-06-01       Impact factor: 4.104

5.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

6.  Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience.

Authors:  Darko Pucar; Amita Shukla-Dave; Hedvig Hricak; Chaya S Moskowitz; Kentaro Kuroiwa; Semra Olgac; Lanie E Ebora; Peter T Scardino; Jason A Koutcher; Kristen L Zakian
Journal:  Radiology       Date:  2005-06-21       Impact factor: 11.105

7.  Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study.

Authors:  Timothy R Nathan; Douglas E Whitelaw; Stanley C Chang; William R Lees; Paul M Ripley; Heather Payne; Linda Jones; M Constance Parkinson; Mark Emberton; Alison R Gillams; Anthony R Mundy; Stephen G Bown
Journal:  J Urol       Date:  2002-10       Impact factor: 7.450

8.  Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker.

Authors:  Vicki Plaks; Natalia Koudinova; Uri Nevo; Jehonathan H Pinthus; Hannah Kanety; Zelig Eshhar; Jacob Ramon; Avigdor Scherz; Michal Neeman; Yoram Salomon
Journal:  Neoplasia       Date:  2004 May-Jun       Impact factor: 5.715

Review 9.  Photodynamic therapy: a new approach to prostate cancer.

Authors:  Rolf Muschter
Journal:  Curr Urol Rep       Date:  2003-06       Impact factor: 2.862

Review 10.  Promise and challenge: Markers of prostate cancer detection, diagnosis and prognosis.

Authors:  D A Troyer; J Mubiru; R J Leach; S L Naylor
Journal:  Dis Markers       Date:  2004       Impact factor: 3.434

View more
  18 in total

Review 1.  Imaging and photodynamic therapy: mechanisms, monitoring, and optimization.

Authors:  Jonathan P Celli; Bryan Q Spring; Imran Rizvi; Conor L Evans; Kimberley S Samkoe; Sarika Verma; Brian W Pogue; Tayyaba Hasan
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

2.  Therapeutic Enhancement of Verteporfin-mediated Photodynamic Therapy by mTOR Inhibitors.

Authors:  Daniel Kraus; Pratheeba Palasuberniam; Bin Chen
Journal:  Photochem Photobiol       Date:  2019-12-17       Impact factor: 3.421

Review 3.  Photodynamic therapy for prostate cancer--a review of current status and future promise.

Authors:  Caroline M Moore; Doug Pendse; Mark Emberton
Journal:  Nat Clin Pract Urol       Date:  2009-01

4.  Diffusion-weighted MRI for monitoring tumor response to photodynamic therapy.

Authors:  Hesheng Wang; Baowei Fei
Journal:  J Magn Reson Imaging       Date:  2010-08       Impact factor: 4.813

5.  Image-guided Interstitial Photodynamic Therapy for Squamous Cell Carcinomas: Preclinical investigation.

Authors:  Mirabelle Sajisevi; Nestor R Rigual; David A Bellnier; Mukund Seshadri
Journal:  J Oral Maxillofac Surg Med Pathol       Date:  2015-03

6.  3D Registration of mpMRI for Assessment of Prostate Cancer Focal Therapy.

Authors:  Clément Orczyk; Andrew B Rosenkrantz; Artem Mikheev; Arnauld Villers; Myriam Bernaudin; Samir S Taneja; Samuel Valable; Henry Rusinek
Journal:  Acad Radiol       Date:  2017-11-06       Impact factor: 3.173

7.  Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models.

Authors:  Kimberley S Samkoe; Alina Chen; Imran Rizvi; Julia A O'Hara; P Jack Hoopes; Stephen P Pereira; Tayyaba Hasan; Brian W Pogue
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-01       Impact factor: 7.038

Review 8.  An update on focal therapy for prostate cancer.

Authors:  Marlon Perera; Nishanth Krishnananthan; Uri Lindner; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2016-09-27       Impact factor: 14.432

9.  Contrast-enhanced ultrasonography for real-time monitoring of interstitial laser thermal therapy in the focal treatment of prostate cancer.

Authors:  Mostafa Atri; Mark R Gertner; Masoom A Haider; Robert A Weersink; John Trachtenberg
Journal:  Can Urol Assoc J       Date:  2009-04       Impact factor: 1.862

10.  Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment.

Authors:  A T Byrne; A E O'Connor; M Hall; J Murtagh; K O'Neill; K M Curran; K Mongrain; J A Rousseau; R Lecomte; S McGee; J J Callanan; D F O'Shea; W M Gallagher
Journal:  Br J Cancer       Date:  2009-10-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.